194 related articles for article (PubMed ID: 23602665)
1. Parenteral immunization with IpaB/IpaD protects mice against lethal pulmonary infection by Shigella.
Martinez-Becerra FJ; Scobey M; Harrison K; Choudhari SP; Quick AM; Joshi SB; Middaugh CR; Picking WL
Vaccine; 2013 May; 31(24):2667-72. PubMed ID: 23602665
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of immunogenicity and protective efficacy of orally delivered Shigella type III secretion system proteins IpaB and IpaD.
Heine SJ; Diaz-McNair J; Martinez-Becerra FJ; Choudhari SP; Clements JD; Picking WL; Pasetti MF
Vaccine; 2013 Jun; 31(28):2919-29. PubMed ID: 23644075
[TBL] [Abstract][Full Text] [Related]
3. Intradermal delivery of Shigella IpaB and IpaD type III secretion proteins: kinetics of cell recruitment and antigen uptake, mucosal and systemic immunity, and protection across serotypes.
Heine SJ; Diaz-McNair J; Andar AU; Drachenberg CB; van de Verg L; Walker R; Picking WL; Pasetti MF
J Immunol; 2014 Feb; 192(4):1630-40. PubMed ID: 24453241
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a novel fusion protein from IpaB and IpaD of Shigella spp. and its potential as a pan-Shigella vaccine.
Martinez-Becerra FJ; Chen X; Dickenson NE; Choudhari SP; Harrison K; Clements JD; Picking WD; Van De Verg LL; Walker RI; Picking WL
Infect Immun; 2013 Dec; 81(12):4470-7. PubMed ID: 24060976
[TBL] [Abstract][Full Text] [Related]
5. Broadly protective Shigella vaccine based on type III secretion apparatus proteins.
Martinez-Becerra FJ; Kissmann JM; Diaz-McNair J; Choudhari SP; Quick AM; Mellado-Sanchez G; Clements JD; Pasetti MF; Picking WL
Infect Immun; 2012 Mar; 80(3):1222-31. PubMed ID: 22202122
[TBL] [Abstract][Full Text] [Related]
6. Vaccination With Mouse Dendritic Cells Loaded With an IpaD-IpaB Fusion Provides Protection Against Shigellosis.
Arizmendi O; Kumar P; Zheng Q; Stewart JP; Picking WD; Picking W; Martinez-Becerra FJ
Front Immunol; 2019; 10():192. PubMed ID: 30800131
[TBL] [Abstract][Full Text] [Related]
7. Shigella IpaB and IpaD displayed on L. lactis bacterium-like particles induce protective immunity in adult and infant mice.
Heine SJ; Franco-Mahecha OL; Chen X; Choudhari S; Blackwelder WC; van Roosmalen ML; Leenhouts K; Picking WL; Pasetti MF
Immunol Cell Biol; 2015 Aug; 93(7):641-52. PubMed ID: 25776843
[TBL] [Abstract][Full Text] [Related]
8. SipD and IpaD induce a cross-protection against Shigella and Salmonella infections.
Jneid B; Rouaix A; Féraudet-Tarisse C; Simon S
PLoS Negl Trop Dis; 2020 May; 14(5):e0008326. PubMed ID: 32463817
[TBL] [Abstract][Full Text] [Related]
9. Assembly, Biochemical Characterization, Immunogenicity, Adjuvanticity, and Efficacy of
Turbyfill KR; Clarkson KA; Vortherms AR; Oaks EV; Kaminski RW
mSphere; 2018; 3(2):. PubMed ID: 29600284
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and protective efficacy offered by a ribosomal-based vaccine from Shigella flexneri 2a.
Shim DH; Chang SY; Park SM; Jang H; Carbis R; Czerkinsky C; Uematsu S; Akira S; Kweon MN
Vaccine; 2007 Jun; 25(25):4828-36. PubMed ID: 17507120
[TBL] [Abstract][Full Text] [Related]
11. Development of recombinant vaccine candidate molecule against Shigella infection.
Chitradevi STS; Kaur G; Sivaramakrishna U; Singh D; Bansal A
Vaccine; 2016 Oct; 34(44):5376-5383. PubMed ID: 27591952
[TBL] [Abstract][Full Text] [Related]
12. Immune response characterization in a human challenge study with a Shigella flexneri 2a bioconjugate vaccine.
Clarkson KA; Talaat KR; Alaimo C; Martin P; Bourgeois AL; Dreyer A; Porter CK; Chakraborty S; Brubaker J; Elwood D; Frölich R; DeNearing B; Weerts HP; Feijoo B; Halpern J; Sack D; Riddle MS; Fonck VG; Kaminski RW
EBioMedicine; 2021 Apr; 66():103308. PubMed ID: 33813141
[TBL] [Abstract][Full Text] [Related]
13. IpaD-loaded N-trimethyl Chitosan Nanoparticles Can Efficiently Protect Guinea Pigs against Shigella flexneri.
Akbari MR; Saadati M; Honari H; Ghorbani HM
Iran J Immunol; 2019 Sep; 16(3):212-224. PubMed ID: 31552830
[TBL] [Abstract][Full Text] [Related]
14. Functional and Antigen-Specific Serum Antibody Levels as Correlates of Protection against Shigellosis in a Controlled Human Challenge Study.
Shimanovich AA; Buskirk AD; Heine SJ; Blackwelder WC; Wahid R; Kotloff KL; Pasetti MF
Clin Vaccine Immunol; 2017 Feb; 24(2):. PubMed ID: 27927680
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of a Shigella flexneri 2a Invaplex 50 intranasal vaccine in adult volunteers.
Tribble D; Kaminski R; Cantrell J; Nelson M; Porter C; Baqar S; Williams C; Arora R; Saunders J; Ananthakrishnan M; Sanders J; Zaucha G; Turbyfill R; Oaks E
Vaccine; 2010 Aug; 28(37):6076-85. PubMed ID: 20619378
[TBL] [Abstract][Full Text] [Related]
16. Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine.
Oaks EV; Turbyfill KR
Vaccine; 2006 Mar; 24(13):2290-301. PubMed ID: 16364513
[TBL] [Abstract][Full Text] [Related]
17. Outer Membrane Vesicles Derived from
Tian H; Li B; Xu T; Yu H; Chen J; Yu H; Li S; Zeng L; Huang X; Liu Q
Appl Environ Microbiol; 2021 Sep; 87(19):e0096821. PubMed ID: 34319809
[TBL] [Abstract][Full Text] [Related]
18. Antibody and cytokine responses in a mouse pulmonary model of Shigella flexneri serotype 2a infection.
van de Verg LL; Mallett CP; Collins HH; Larsen T; Hammack C; Hale TL
Infect Immun; 1995 May; 63(5):1947-54. PubMed ID: 7729907
[TBL] [Abstract][Full Text] [Related]
19. A broadly immunogenic polyvalent
Li S; Anvari S; Ptacek G; Upadhyay I; Kaminski RW; Sack DA; Zhang W
Infect Immun; 2023 Nov; 91(11):e0031623. PubMed ID: 37795982
[TBL] [Abstract][Full Text] [Related]
20. An approach to chimeric subunit immunogen provides efficient protection against toxicity, type III and type v secretion systems of Shigella.
Felegary A; Nazarian S; Kordbacheh E; Fathi J; Minae ME
Int Immunopharmacol; 2021 Nov; 100():108132. PubMed ID: 34508943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
